1-5 of 5
Ping Zhu
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Covalent ERα Antagonist H3B-6545 Demonstrates Encouraging Preclinical Activity in Therapy-Resistant Breast Cancer

Open Access
Craig Furman, Xiaoling Puyang, Zhaojie Zhang, Zhenhua J. Wu, Deepti Banka, Kiran B. Aithal, Lee A. Albacker, Ming-Hong Hao, Sean Irwin, Amy Kim, Meagan Montesion, Alyssa D. Moriarty, Karthikeyan Murugesan, Tuong-Vi Nguyen, Victoria Rimkunas, Tarek Sahmoud, Michael J. Wick, Shihua Yao, Xun Zhang, Hao Zeng, Frédéric H. Vaillancourt, David M. Bolduc, Nicholas Larsen, Guo Zhu Zheng, Sudeep Prajapati, Ping Zhu, Manav Korpal
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2022) 21 (6): 890–902.
https://doi.org/10.1158/1535-7163.MCT-21-0378
Published: 01 June 2022
View articletitled, Covalent ERα Antagonist H3B-6545 Demonstrates Encouraging Preclinical Activity in Therapy-Resistant Breast Cancer
Open the PDF for Covalent ERα Antagonist H3B-6545 Demonstrates Encouraging Preclinical Activity in Therapy-Resistant Breast Cancer in another window
Includes: Supplementary data
Journal Articles

Abstract B125: Mutant SF3B1 downregulates proteins involved in differentiation, including ABCB7

Free
Rachel B. Darman, Samantha A. Perino, Michael Seiler, Shouyong Peng, Jacob Feala, Peter Fekkes, Gregg F. Keaney, Kaiko Kunii, Linda Lee, Kian Huat Lim, Yoshiya Oda, Khin Myint, Esther A. Obeng, Ermira Pazolli, Eun Sun Park, John Yuan Wang, Markus Warmuth, Lihua Yu, Ping Zhu, Yoshiharu Mizui, Benjamin L. Ebert, Peter G. Smith, Silvia Buonamici
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2015) 14 (12_Supplement_2): B125.
https://doi.org/10.1158/1535-7163.TARG-15-B125
Published: 01 December 2015
View articletitled, Abstract B125: Mutant SF3B1 downregulates proteins involved in differentiation, including ABCB7
Journal Articles

Abstract C26: Development of selective MELK kinase inhibitors for breast cancer treatment

Free
Piotr Kowalczyk, Paulina Węgrzyn, Monika Prokopowicz, Martyna Knop, Karolina Mazur, Katarzyna Dziedzic, Karolina Gluza, Martyna Knop, Katarzyna Dziedzic, Karolina Mazur, Adam Radzimierski, Claude Commandeur, Magdalena Zawadzka, Kristjan Bloudoff, Fred Vaillancourt, Nick Larsen, John Wang, Dom Reynolds, Daisuke Ito, Jian Zou, Michelle Aicher, Pete Smith, Ping Zhu, Krzysztof Brzózka
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2015) 14 (12_Supplement_2): C26.
https://doi.org/10.1158/1535-7163.TARG-15-C26
Published: 01 December 2015
View articletitled, Abstract C26: Development of selective MELK kinase inhibitors for breast cancer treatment
Journal Articles

Abstract C8: Targeting MCL1-dependent cancers with SF3B splicing modulators

Free
Daniel Aird, Ermira Pazolli, Craig Furman, Linda Lee, Kaiko Kunii, Eun Sun Park, Craig Karr, Betty Chan, Michelle Aicher, Silvia Buonamici, John Yuan Wang, Jacob Feala, Lihua Yu, Markus Warmuth, Peter Smith, Peter Fekkes, Ping Zhu, Baudouin Gerard, Yoshiharu Mizui, Laura Corson
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2015) 14 (12_Supplement_2): C8.
https://doi.org/10.1158/1535-7163.TARG-15-C8
Published: 01 December 2015
View articletitled, Abstract C8: Targeting MCL1-dependent cancers with SF3B splicing modulators
Journal Articles

Abstract B40: X-MANTM isogenic disease models: Precision tools for synthetic lethality screening

Free
Jo Francis, Jessica Hunt, Kyla Grimshaw, Agustin Chicas, Lihua Yu, Ping Zhu, Markus Warmuth, Chris Torrance
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2013) 12 (5_Supplement): B40.
https://doi.org/10.1158/1535-7163.PMS-B40
Published: 01 May 2014
View articletitled, Abstract B40: X-MANTM isogenic disease models: Precision tools for synthetic lethality screening